Profile data is unavailable for this security.
About the company
Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. It manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. It is also developing oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).
- Revenue in USD (TTM)40.86bn
- Net income in USD8.37bn
- Incorporated1901
- Employees43.00k
- LocationEli Lilly and CoLilly Corporate Ctr, Drop Code 1094INDIANAPOLIS 46285-0001United StatesUSA
- Phone+1 (317) 276-2000
- Fax+1 (317) 276-3492
- Websitehttps://www.lilly.com/
Mergers & acquisitions
| Acquired company | LLY:NYQ since announced | Transaction value |
|---|---|---|
| Morphic Holding Inc | -18.56% | 3.19bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen Inc | 32.53bn | 4.23bn | 154.74bn | 26.70k | 36.83 | 20.56 | 15.78 | 4.76 | 7.82 | 7.82 | 60.33 | 14.00 | 0.3587 | 2.08 | 4.83 | 1,218,502.00 | 4.66 | 10.36 | 5.87 | 13.06 | 60.48 | 75.41 | 13.00 | 26.51 | 0.9553 | 2.62 | 0.8892 | 59.54 | 7.09 | 3.49 | 2.52 | -4.36 | 8.54 | 10.04 |
| Merck & Co Inc | 63.17bn | 12.15bn | 246.49bn | 72.00k | 20.43 | 5.54 | 15.00 | 3.90 | 4.77 | 4.77 | 24.95 | 17.58 | 0.5634 | 2.39 | 5.80 | 877,416.70 | 10.85 | 7.70 | 14.19 | 10.29 | 76.59 | 72.26 | 19.25 | 15.03 | 1.15 | 24.33 | 0.4611 | 89.55 | 1.40 | 7.29 | -97.49 | -43.80 | 8.12 | 8.26 |
| AbbVie Inc | 55.53bn | 5.08bn | 296.46bn | 50.00k | 58.53 | 49.15 | 21.94 | 5.34 | 2.87 | 2.87 | 31.32 | 3.41 | 0.3972 | 4.31 | 4.85 | 1,110,660.00 | 3.67 | 6.55 | 5.09 | 8.40 | 67.25 | 69.74 | 9.24 | 16.46 | 0.5419 | 7.88 | 0.9213 | 111.46 | -6.44 | 10.65 | -59.09 | -3.44 | 4.02 | 10.52 |
| Johnson & Johnson | 87.70bn | 14.77bn | 368.63bn | 131.90k | 25.17 | 5.25 | 16.72 | 4.20 | 6.08 | 6.05 | 36.12 | 29.14 | 0.5094 | 2.27 | 5.66 | 664,867.30 | 8.58 | 8.93 | 11.90 | 11.96 | 69.16 | 68.17 | 16.84 | 18.86 | 0.7853 | -- | 0.3376 | 71.25 | 6.46 | 0.8622 | -18.59 | -2.72 | 4.36 | 5.83 |
| Eli Lilly And Co | 40.86bn | 8.37bn | 715.22bn | 43.00k | 81.38 | 50.25 | 71.24 | 17.50 | 9.26 | 9.26 | 45.19 | 14.99 | 0.6121 | 1.26 | 4.43 | 950,309.30 | 12.54 | 11.71 | 19.31 | 17.33 | 80.91 | 77.34 | 20.48 | 20.24 | 0.9709 | 33.82 | 0.6849 | 58.45 | 19.56 | 9.69 | -16.08 | 9.52 | 19.62 | 14.97 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 70.16m | 7.39% |
| PNC Bank, NA (Investment Management)as of 30 Sep 2024 | 51.35m | 5.41% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 41.08m | 4.33% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 33.85m | 3.57% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 29.27m | 3.08% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 20.36m | 2.14% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 19.81m | 2.09% |
| PRIMECAP Management Co.as of 30 Sep 2024 | 17.69m | 1.86% |
| Geode Capital Management LLCas of 30 Sep 2024 | 17.09m | 1.80% |
| State Farm Investment Management Corp.as of 30 Sep 2024 | 12.65m | 1.33% |
